Merck Sharp + Dohme Corp.

Orchid Pharma Ltd.

Shuzhi Dong

Alexander Pasternak

Jinlong Jiang

Fa-Xiang Ding

Xin Gu

Haifeng Tang

Takao Suzuki

Li Xiao

Haiqun Tang

Dexi Yang

Jessica Frie

Zhiqiang Zhao

Katherine Young

Barbara A Pio

Jack D Scott

Yuhua Huang

Joseph P Vacca

Frank W Bennett

Zhicai Wu

Shawn P Walsh

Jing Su

Jianmin Fu

Harry R Chobanian

Zhibo Zhang

William K Hagmann

Dooseop Kim

Guoqing Li

Ian W Davies

Yan Guo

Weidong Pan

Mihir Mandal

Qinghong Fu

Shu-Wei Yang

Xu Zhang

Ravi P Nargund

Michael W Miller

Sheo B Singh

Yong Zhang

Helen Y Chen

Tao Yu

Timothy A Blizzard

Shouning Xu

Yang Yu

Dipshikha Biswas

Zhifa Pu

David N Hunter

Reynalda K DeJesus

Reynalda DeJesus

Clare London

Jacqueline D Hicks

Jianping Pan

Aurash Shahripour

Timothy Allen Blizzard

Zhiyong Hu

Hongwu Wang

Ming Wang

Ronald Dale Ferguson, Ii

Hong Dong Chu

Gopalan Balasubramanian

Yunfeng Bai

Zhixiang Zheng

Cangming Yang

Reynalda Keh Dejesus

Matthew Lombardo

Candido Gude

Zack Zhiqiang Guo

Venkatesan Parameswaran

Reynalda De Jesus

Maneesh Paul-Satyaseela

Hariharan Periasamy

Alex Pasternak

Michael Wayne Miller

Chidambaram Venkateswaran Srinivasan

Sridhar Ramanathan Iyer

Bharani Thirunavukkarasu

Prabhakar Rao Gunturu

Manjula Devi Deshkumar

Jinglong Jiang

Venkateshwarlu Jakkala

Frank Bennett

Sheo Singh

Michael Miller

David Hunter

Reynalda Dejesus

Reynalda K Dejesus

Ronald Dale Ii Ferguson

Reynalda Keh De Jesus

Zhieai Wu

The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of structural formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of structural formula I, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Chromane amidine monobactam compounds for the treatment of bacterial infections

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

Metallo-beta-lactamase inhibitors and methods of use thereof

This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R, and Rare as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Substituted carbapenems for the treatment of bacterial infections

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Metallo-beta-lactamase inhibitors

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

Metallo-&#x3b2;-lactamase inhibitors

The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of Formula (I); and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassim channel

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

The present invention relates to compounds of formula I that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included. 

Growing community of inventors

Plainsboro, NJ, United States of America

Shuzhi Dong